World Stroke Organization 
Description: This webinar brings together leading international experts to explore the latest advances in antithrombotic therapy for stroke prevention. The session will review the mechanisms and therapeutic rationale behind emerging agents currently under investigation, including next-generation anticoagulants and antiplatelet therapies. Particular attention will be given to Factor XI/XIa inhibitors and other innovative approaches that may redefine the safety–efficacy paradigm in both primary and secondary stroke prevention. Participants will gain critical insights into key findings from recent and ongoing clinical trials and will discuss how these developments may shape future clinical practice.
Learning Objectives:
- Describe the mechanistic rationale of emerging antithrombotic agents targeting Factor XIa for secondary stroke prevention
- Summarize key results from recent Phase II and Phase III trials evaluating efficacy and safety of FXIa inhibition in combination with antiplatelet therapy after non-cardioembolic ischemic stroke
- Discuss potential implications of these innovative therapies on current clinical best practices for secondary stroke prevention
Chair: Prof. Valeria Caso
Speakers and Topics:
- Assoc. Prof. Ashkan Shoamanesh – Targeting Factor XIa: Mechanistic Rationale for a Safer Antithrombotic Strategy in Secondary Stroke Prevention
- Prof. Mike Sharma – Factor XIa Inhibition After Non-Cardioembolic Stroke: Lessons from Phase II and III Clinical Trials
- Assoc. Prof. Xin Cheng – Redefining Secondary Stroke Prevention: Clinical Implications of Factor XIa Inhibition
This webinar is supported by an unrestricted educational grant by Bayer AG.
Please note the webinar recording will be translated into the following languages: Japanese, Chinese, Portuguese, Spanish, Italian, French, German
Date & Time: Wednesday March 18th, 2026 13:30-14.30 (CET)
Webinar Details
Speakers:
- Assoc. Prof. Ashkan Shoamanesh, Associate Professor of Medicine and Stroke Neurologist at McMaster University, Director of the Hemorrhagic Stroke Research Program at PHRI, Canada
- Prof. Mike Sharma, Stroke Neurologist and Associate Professor at the University of Ottawa, Canada
- Assoc. Prof Xin Cheng, Chief Physician and Vice Chair of the Department of Neurology, Huashan Hospital, Fudan University, National Center for Neurological Disorders, Shanghai, China
Moderator:
- Prof. Valeria Caso, Chief of Neurology-Stroke Unit, Ospedale di Saronno, Italy
